Spots Global Cancer Trial Database for Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)

Official Title: Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)

Study ID: NCT02608346

Conditions

Women With BRCA1 Germline Deleterious Mutation

Interventions

Blood sampling

Study Description

Brief Summary: BRCA1 carriers who are at high risk of developing either a relapse and/or a new cancer growth will be included. These patients will be followed up during 30 months (2,5 years) with mutated TP53 mutation detection or during 42 months (3,5 years) with mutated TP53 mutation detection and circulating tumor cells detection (CTC) performed at each hospital visit (for technical reason only patients included at Institut Curie will be proposed to participate to the CTC substudy).

Detailed Description: